KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells

KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET‐expressing tumor cells

The MET receptor tyrosine kinase is often deregulated in human cancers and several MET inhibitors are evaluated in clinical trials. Similarly to EGFR, MET signals through the RAS‐RAF‐ERK/MAPK pathway which plays key roles in cell proliferation and survival. Mutations of genes encoding for RAS protei...

Full description

Saved in:
Bibliographic Details
Main Authors: Dominic Leiser, Michaela Medová, Kei Mikami, Lluís Nisa, Deborah Stroka, Andree Blaukat, Friedhelm Bladt, Daniel M. Aebersold, Yitzhak Zimmer
Format: Article
Language:English
Published: Wiley 2015-08-01
Series:Molecular Oncology
Subjects:
MET
RAS
Mutations
Small molecule inhibitors
Resistance
Online Access:https://doi.org/10.1016/j.molonc.2015.04.001
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1016/j.molonc.2015.04.001

Similar Items